Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination

Tombácz, István; Weissman, Drew; Pardi, Norbert

doi:10.1007/978-1-0716-0872-2_2

Cited by 46 publications

(35 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The candidate mRNA is typically delivered in a lipid nanoparticle (LNP), increasing its stability in vivo and ability to successfully enter the host's cells and be delivered to the cytosol. Advances in nanotechnology have resulted in the development of efficient carriers which are generally nontoxic, and ideally nonimmunogenic, allowing for repeated dosing of the LNP-mRNA system 12 .…”

Section: Mrna Vaccinesmentioning

confidence: 99%

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic

et al. 2021

View full text Add to dashboard Cite

Adenoviral vectors have been explored as vaccine agents for a range of infectious diseases, and their ability to induce a potent and balanced immune response made them logical candidates to apply to the COVID-19 pandemic. The unique molecular characteristics of these vectors enabled the rapid development of vaccines with advanced designs capable of overcoming the biological challenges faced by early adenoviral vector systems. These successes and the urgency of the COVID-19 situation have resulted in a flurry of candidate adenoviral vector vaccines for COVID-19 from both academia and industry. These vaccines represent some of the lead candidates currently supported by Operation Warp Speed and other government agencies for rapid translational development. This review details adenoviral vector COVID-19 vaccines currently in human clinical trials and provides an overview of the new technologies employed in their design. As these vaccines have formed a cornerstone of the COVID-19 global vaccination campaign, this review provides a full consideration of the impact and development of this emerging platform.

show abstract

Section: Mrna Vaccinesmentioning

confidence: 99%

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic

et al. 2021

View full text Add to dashboard Cite

show abstract

“…We are attesting the success of mRNA vaccines against SARS-CoV-2 infection, and current data suggest that mRNA-based vaccines provide a flexible, rapid, and scalable platform for immunizations (Tombácz et al, 2021). This innovative tool parallels the recent explosion of monoclonal antibodies technologies.…”

Section: Discussionmentioning

confidence: 90%

COVID-19 and Preparing for Future Ecological Crises: Hopes from Metagenomics in Facing Current and Future Viral Pandemic Challenges

Fulci

Carissimi

Laudadio

2021

OMICS: A Journal of Integrative Biology

View full text Add to dashboard Cite

The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak demonstrates the potential of coronaviruses, especially bat-derived beta coronaviruses to rapidly escalate to a global pandemic that has caused deaths in the order of several millions already. The huge efforts put in place by the scientific community to address this emergency have disclosed how the implementation of new technologies is crucial in the prepandemic period to timely face future ecological crises. In this context, we argue that metagenomics and new approaches to understanding ecosystems and biodiversity offer veritable prospects to innovate therapeutics and diagnostics against novel and existing infectious agents. We discuss the opportunities and challenges associated with the science of metagenomics, specifically with an eye to inform and prevent future ecological crises and pandemics that are looming on the horizon in the 21st century.

show abstract

“…Recent technological advances have largely overcome issues with the instability of mRNA and the difficulty of delivering it into cells, and some mRNA vaccines have demonstrated encouraging early results. mRNA-based vaccines have important advantages over other vaccine approaches, including outstanding efficacy, safety, and the potential for rapid, inexpensive, and scalable production [ 90 ]. A rabies vaccine for pigs has been reported as an example of this vaccine platform [ 91 ].…”

Section: Compositionmentioning

confidence: 99%

Future perspectives on swine viral vaccines: where are we headed?

et al. 2021

View full text Add to dashboard Cite

Deliberate infection of humans with smallpox, also known as variolation, was a common practice in Asia and dates back to the fifteenth century. The world’s first human vaccination was administered in 1796 by Edward Jenner, a British physician. One of the first pig vaccines, which targeted the bacterium Erysipelothrix rhusiopathiae, was introduced in 1883 in France by Louis Pasteur. Since then vaccination has become an essential part of pig production, and viral vaccines in particular are essential tools for pig producers and veterinarians to manage pig herd health. Traditionally, viral vaccines for pigs are either based on attenuated-live virus strains or inactivated viral antigens. With the advent of genomic sequencing and molecular engineering, novel vaccine strategies and tools, including subunit and nucleic acid vaccines, became available and are being increasingly used in pigs. This review aims to summarize recent trends and technologies available for the production and use of vaccines targeting pig viruses.

show abstract

Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination

Cited by 46 publications

References 118 publications

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic

COVID-19 and Preparing for Future Ecological Crises: Hopes from Metagenomics in Facing Current and Future Viral Pandemic Challenges

Future perspectives on swine viral vaccines: where are we headed?

Contact Info

Product

Resources

About